Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Total revenue | 1,458 | 865 |
| Operating expenses: | ||
| Research and development | 68,574 | 72,484 |
| General and administrative | 17,183 | 19,296 |
| Collaboration expense, net | 45,949 | 57,509 |
| Total operating expenses | 131,706 | 149,289 |
| Loss from operations | (130,248) | (148,424) |
| Other income: |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's G&A?
- CRISPR Therapeutics (CRSP) reported G&A of $17.18M in Q1 2026.
- How has CRISPR Therapeutics's G&A changed year-over-year?
- CRISPR Therapeutics's G&A decreased by 11.0% year-over-year, from $19.3M to $17.18M.
- What is the long-term trend for CRISPR Therapeutics's G&A?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's G&A has grown at a -7.6% compound annual growth rate (CAGR), from $100.71M to $73.54M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about CRISPR Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude